You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天士力(600535.SH):收到複方丹蔘滴丸的藥品補充申請批准通知書
格隆匯 10-12 15:52

格隆匯10月12日丨天士力(600535.SH)公佈,近日,公司收到國家藥品監督管理局核准簽發的《藥品補充申請批准通知書》。

藥品名稱:複方丹蔘滴丸;規格:每丸重27mg;申請內容:增加中藥的功能主治。

複方丹蔘滴丸是由公司獨家開發研製的一種治療心血管疾病的複方中藥,於1993年獲得新藥證書和生產批件,1995年上市,為國家醫保目錄品種、國家基本藥物目錄品種、國家基藥低價藥品目錄品種。複方丹蔘滴丸由丹蔘、三七、冰片組成,具有活血化瘀,理氣止痛的功效,用於氣滯血瘀所致的胸痺,症見胸悶、心前區刺痛;冠心病心絞痛見上述症候者。

截至公吿日,公司對該項目累計研發投入為人民幣4128.01萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account